OakChart

Heartflow Inc

HTFLHealthcare·Health Information Services·USA·Mid·NASD·Nov 11 • 8:23 AM ET

55.800.00 (0.00%)
2026-11-11 14:58 CET
Market cap
4,852.01 USD m
Revenue, TTM
212.07 USD m
Net income, TTM
-118.37 USD m
Free cash flow, TTM
-59.18 USD m
EPS diluted, TTM
-1.40
P/E
-
Compare

Price

HTFL against its 20, 50 and 200-day averages
2050200missearnings
30.0040.0050.0060.006.2M12.5MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26HTFLclose 55.8020-day 55.2750-day 51.67200-day 34.9655.80

7.9% under 60.56 on 29 Oct 2026. Last 15 sessions, 18.6% high to low

Profile

HTFL
52-week range, 88% of the way up
20.1360.56

HeartFlow, Inc. operates as a cardiovascular company which engages in diagnosing coronary artery diseases. The firm provides a patient-specific analysis of coronary blood flow utilizing coronary CT scans and proprietary computer algorithms based on computational fluid dynamics. The company was founded by Charles A. Taylor, Nathan M. Wilson, and Christopher K. Zarins in July 2007 and is headquartered in San Francisco, CA.

IndexRUT
Employees843
IPOAug 08, 2025
Beta2.58
ATR, 14d2.98
Rel volume0.00
Short float8.77%
Insider own25.40%
Inst own82.92%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap4.85B
Enterprise Value4.72B
Income-118.37M
Sales212.07M
Book/sh3.23
Cash/sh1.87
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees843
IPOAug 08, 2025

Ratios

P/E-
Forward P/E-
PEG-
P/S22.88
P/B17.30
P/C29.85
P/FCF-
EV/EBITDA-
EV/Sales22.24
Quick Ratio4.87
Current Ratio4.87
Debt/Eq0.10
LT Debt/Eq0.07
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.40
EPS next Y-0.27
EPS next Q-0.10
EPS this Y74.40%
EPS next Y34.83%
EPS next 5Y-
EPS past 3/5Y5.20% -
Sales past 3/5Y42.10% -
EPS Y/Y TTM-
Sales Y/Y TTM-
EPS Q/Q-65.19%
Sales Q/Q47.57%
EarningsNov 12 AMC
EPS/Sales Surpr.47.64% 13.15%

Ownership

Insider Own25.40%
Insider Trans-2.19%
Inst Own82.92%
Inst Trans32.78%
ROA-46.99%
ROE-154.23%
ROIC-39.45%
Gross Margin80.08%
Oper. Margin-34.31%
Profit Margin-55.82%
SMA200.96%
SMA507.99%
SMA20059.60%
Trades-

Technical

Shs Outstand86.72M
Shs Float64.87M
Short Float8.77%
Short Ratio2.86
Short Interest5.69M
52W High60.56 -7.86%
52W Low20.13 177.20%
Volatility6.32% 5.94%
ATR (14)2.98
RSI (14)54.46
Beta2.58
Rel Volume0.00
Avg Volume1.99M
Volume177

Performance

Perf Week-1.36%
Perf Month10.89%
Perf Quarter79.94%
Perf Half Y78.85%
Perf YTD91.42%
Perf Year63.30%
Perf 3Y-
Perf 5Y-
Perf 10Y-
Recom1.33
Target Price50.50
Prev Close55.80
Price55.80
Change %0.00%

Analyst ratings

latest 9 of 9
DateActionAnalystRating changeTargetImplied
Sep 09, 2026ResumedUUBSNeutral$55-1.4%
Jul 31, 2026InitiatedRRobert W. BairdOutperform$34-39.1%
May 04, 2026InitiatedWWilliam BlairOutperform
Jan 28, 2026InitiatedWWells FargoOverweight$38-31.9%
Sep 02, 2025InitiatedSStifelBuy$35-37.3%
Sep 02, 2025InitiatedPPiper SandlerOverweight$38-31.9%
Sep 02, 2025InitiatedMMorgan StanleyEqual-Weight$35-37.3%
Sep 02, 2025InitiatedJJP MorganOverweight$36-35.5%
Sep 02, 2025InitiatedCCanaccord GenuityBuy$35-37.3%

Peers

Mkt cap
TickerCompanyMkt cap
TEMTempus AI Inc15.16B
RDNTRadnet Inc6.25B
IRTCiRhythm Holdings Inc3.00B
GEHCGE HealthCare Technologies Inc37.72B
SOPHSOPHiA Genetics SA652.07M
BFLYButterfly Network Inc1.80B
PHGKoninklijke Philips NV ADR29.21B
CBLLCeribell Inc1.07B
NNOXNano X Imaging Ltd31.16M
HSCSHeartSciences Inc12.00M

Insider trading

latest 14 of 98
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Farquhar John C.M.Chief Executive OfficerNov 10 '26Option Exercise2.2215,62034,676290,883Nov 10 06:59 PM
Farquhar John C.M.Chief Executive OfficerNov 10 '26Sale55.7438,9002,168,286251,983Nov 10 06:59 PM
Verghese VikramChief Financial OfficerNov 09 '26Sale53.153,587190,649149,587Nov 10 06:52 PM
Farquhar John C.M.OfficerNov 10 '26Proposed Sale55.7438,9002,168,286Nov 10 09:47 AM
Verghese VikramOfficerNov 09 '26Proposed Sale53.153,587190,649Nov 09 10:08 AM
Rogers CampbellChief Medical OfficerOct 22 '26Option Exercise6.5417,430114,02597,386Oct 26 06:00 PM
Rogers CampbellChief Medical OfficerOct 22 '26Sale55.0123,9331,316,55473,453Oct 26 06:00 PM
Rogers CampbellOfficerOct 22 '26Proposed Sale55.0123,9331,316,554Oct 22 11:09 AM
Rogers CampbellMember of immediate family ofOct 22 '26Proposed Sale55.015,654311,027Oct 22 10:34 AM
Farquhar John C.M.Chief Executive OfficerOct 12 '26Sale49.5738,9001,928,195283,014Oct 14 06:05 PM
Farquhar John C.M.OfficerOct 12 '26Proposed Sale49.5738,9001,928,195Oct 13 08:21 AM
Rogers CampbellChief Medical OfficerSep 18 '26Option Exercise7.9413,179104,58899,638Sep 21 06:19 PM
Rogers CampbellChief Medical OfficerSep 18 '26Sale50.1519,682987,05279,956Sep 21 06:19 PM
Verghese VikramChief Financial OfficerSep 18 '26Sale50.7516,766850,926155,183Sep 18 08:46 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VBRVanguard Morningstar Small-Cap Value ETFAUM: 37.76B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 138
  • Heartflow Must Prove Its Flat Second-Half Guide Is Conservative After A 39% Rally (Earnings Whispers) -8.17%
  • AHA 2026: Heartflow Plaque Analysis Associated with 34% Fewer Major CVD Events and Half the Rate of Heart Attack at One Year in Prospective DECIDE Registry (GlobeNewswire) -7.72%
  • TCT 2026: CT-guided PCI Matches IVUS Outcomes in Randomized P4 Trial; Heartflow PCI Navigator Changes PCI Plans in Approximately 70% of Patients (GlobeNewswire)
  • Heartflow to Report Third Quarter 2026 Financial Results on November 12, 2026 (GlobeNewswire) +5.65% +8.96%
  • Late Breaking Data from Independent Government-Funded Trial at ESC Shows Heartflow FFRCT Analysis Reduces Unnecessary Invasive Heart Procedures by Nearly Half (GlobeNewswire)
  • Loading…
  • Heartflow to Participate in the Wells Fargo 21st Annual Healthcare Conference (GlobeNewswire)
  • This AI-Tied IPO Stock Just Broke Out On Its 'Outsized' Guidance Boost (Investor's Business Daily) +35.70%
  • HeartFlow Inc (HTFL) (Q2 2026) Earnings Call Highlights: Revenue Surges 48% and Plaque Momentum ... (GuruFocus.com)
  • HeartFlow: Q2 Earnings Snapshot (Associated Press)
  • Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance (GlobeNewswire)
  • HeartFlow Inc (HTFL) Q2 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
  • Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls (The Fly)
  • Heartflow to Report Second Quarter 2026 Financial Results on August 13, 2026 (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-12--0.103--65.198
2026Q22026-08-13-0.070-0.134-0.18064.0856.648
2026Q12026-05-14-0.160-0.188-0.32052.5949.717
2025Q42026-03-18-0.120-0.169-0.28649.1346.586
2025Q32025-11-12-0.270-0.242-0.60946.2842.034
2025Q22025-09-03-0.153-0.213-0.11043.3143.204
2025Q12025-05-28-0.461--0.39937.20--
2026Q4---0.091--66.728
2027Q1---0.087--71.626
2027Q2---0.061--77.456
2027Q3---0.058--78.996
2027Q4---0.041--82.166
2028Q1--0.007--89.341
2028Q2--0.033--93.471
2028Q3--0.041--95.581
2028Q4--0.037--97.881

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2025FY-1.620-1.932-3.170176.03173.41
2026FY--0.415--248.62
2027FY--0.270--308.55
2028FY-0.078--374.91
2029FY-0.440--464.5
2030FY-0.700--545.85

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-0290065.1964.6065.90
2026Q3S2026-10-2890065.2064.6065.90
2026Q3S2026-10-1498065.2064.6065.90
2026Q3S2026-10-0998065.1964.6065.90
2026Q3S2026-10-0698065.1964.6065.90
2026Q3S2026-09-2198065.2664.7965.90
2026Q3S2026-09-0898065.2664.8065.90
2026Q3S2026-08-1488065.2764.8065.90
2026Q3S2026-08-1380059.3458.7059.73
2026Q3S2026-07-3080059.3458.7059.73
2026Q3S2026-07-2970059.2958.7059.70
2026Q3S2026-06-2976059.2958.7059.70
2026Q3S2026-05-1566059.2358.7359.70
2026Q3S2026-05-0164056.8856.6057.29

Estimate history

EPS, annual-1.524-1.188-1.37-1.3972
Period202320242025TTM
EPS, quarterly-0.258-0.399-0.11-0.609-0.286-0.32-0.182
PeriodQ1 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual87.174125.808176.034212.07
Period202320242025TTM
Sales, quarterly26.84337.20543.42446.27649.1352.58764.082
PeriodQ1 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual81.16881.16885.28186.717
Period202320242025MRQ
Shares, quarterly81.16881.16883.39683.47485.28186.10586.717
PeriodQ1 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Total Revenue212.07176.03125.8187.17
Cost of Goods Sold Incl. D&A42.2440.8431.3629.12
Gross Profit169.83135.2094.4558.05
Selling, General and Administrative Excl. Other242.60199.26155.67130.97
Research and Development83.8464.9243.5235.85
Other Operating Expense0.000.000.000.00
Operating Income-72.77-64.07-61.22-72.91
Interest Expense3.4615.1722.7724.69
Unusual Expense50.4542.9416.623.28
Net Income Before Taxes-118.46-116.87-96.37-95.11
Income Taxes-0.09-0.080.050.55
Consolidated Net Income-118.37-116.79-96.43-95.66
Net Income From Continuing Operations-118.37-116.79-96.43-95.66
Net Income-118.37-116.79-96.43-123.69
EPS (Recurring)-0.96-1.02-1.04-1.50
EPS (Basic, Before Extraordinaries)-1.40-1.37-1.19-1.52
EPS (Diluted)-1.40-1.37-1.19-1.52
EBITDA-63.74-55.49-53.13-65.28
Non-Operating Income (Expense)8.225.324.235.78
Other After Tax Adjustments0.000.000.000.00
Stock Option Compensation Expense18.7111.038.079.88
Price To Sales Ratio11.9514.12--
Gross Margin80.0876.8075.0766.59
Operating Margin-34.31-36.39-48.66-83.64
Net Margin-55.82-66.35-76.65-141.89
Shares Outstanding86.7285.2881.1781.17
Market Capitalization4,852.014,852.012,572.64-

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q1
Total Revenue64.0852.5949.1346.2843.4237.2026.84
Cost of Goods Sold Incl. D&A10.8910.4210.0710.8610.659.267.42
Gross Profit53.1942.1639.0635.4132.7827.9419.42
Selling, General and Administrative Excl. Other71.0964.1956.8150.5146.4945.4435.48
Research and Development26.2621.6218.6617.3015.0313.929.44
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-17.90-22.02-17.75-15.10-13.71-17.50-16.06
Interest Expense0.000.000.013.456.625.096.24
Unusual Expense0.007.489.3133.66-10.6810.650.06
Net Income Before Taxes-15.72-27.36-24.56-50.83-9.14-32.34-21.00
Income Taxes0.020.02-0.170.030.060.00-0.07
Consolidated Net Income-15.74-27.38-24.39-50.85-9.20-32.34-20.93
Net Income From Continuing Operations-15.74-27.38-24.39-50.85-9.20-32.34-20.93
Net Income-15.74-27.38-24.39-50.85-9.20-32.34-20.93
EPS (Recurring)-0.18-0.26-0.21-0.33-0.20-0.31-0.26
EPS (Basic, Before Extraordinaries)-0.18-0.32-0.29-0.61-0.11-0.40-0.26
EPS (Diluted)-0.18-0.32-0.29-0.61-0.11-0.40-0.26
EBITDA-15.64-19.59-15.50-13.01-11.57-15.41-14.20
Non-Operating Income (Expense)2.182.152.511.380.520.901.36
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense6.255.184.163.131.782.492.15
Price To Sales Ratio11.9510.8914.12----
Gross Margin83.0080.1879.5176.5375.4875.1072.36
Operating Margin-27.93-41.88-36.13-32.63-31.58-47.04-59.82
Net Margin-24.57-52.07-49.65-109.89-21.18-86.94-77.98
Shares Outstanding86.7286.1185.2883.4783.4081.1781.17
Market Capitalization4,852.012,086.482,482.382,807.112,877.17--

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY
Cash & Short Term Investments176.7951.52122.77
Short Term Receivables29.3424.6420.55
Inventories0.000.000.00
Other Current Assets7.413.683.18
Total Current Assets213.5379.83146.49
Net Property, Plant & Equipment26.0727.7330.88
Total Investments and Advances108.074.334.47
Other Assets11.776.823.21
Total Assets359.45118.70185.05
Short Term Debt Incl. Current Port. of LT Debt5.925.425.14
Accounts Payable3.172.872.89
Other Current Liabilities33.2825.3224.79
Total Current Liabilities42.3733.6032.81
Long Term Debt16.13154.97155.46
Provision for Risks Charges0.000.000.00
Other Liabilities0.3021.055.77
Total Liabilities58.80209.62194.05
Non-Equity Reserves0.000.000.00
Preferred Stock - Carrying Value0.00768.57768.57
Common Equity300.65-859.48-777.56
Total Shareholders Equity300.65-90.92-9.00
Accumulated Minority Interest0.000.000.00
Total Equity300.65-90.92-9.00
Total Liabilities & Stockholders Equity359.45118.70185.05
Book Value Per Share3.53-10.59-9.58
Tangible Book Value Per Share3.53-10.59-9.58
Full-Time Employees843--
Price to Book Ratio17.309.91-
Return on Assets-48.85-63.49-
Return on Equity-111.37--
Return on Invested Capital-36.87-150.55-65.31
Quick Ratio5.042.384.46
Current Ratio5.042.384.46

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY
Net Income-118.37-116.79-96.43-95.66
Depreciation9.038.578.097.63
Other Funds (Non Cash)72.9461.8630.2120.13
Funds from Operations-36.40-46.36-58.12-67.89
Extraordinary Item0.000.000.000.00
Changes in Working Capital-15.83-7.66-10.88-8.54
Cash from Operating Activities-52.23-54.02-69.00-76.43
Capital Expenditures-6.95-5.03-4.36-6.11
Net Assets From Acquisitions0.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.00
Purchase or Sale of Investments-209.93-233.540.000.00
Purchase of Investments-278.86-233.540.000.00
Sale Or Maturity of Investments68.920.000.000.00
Other Uses0.000.000.000.00
Other Sources0.000.000.000.00
Cash from Investing Activities-216.88-238.57-4.36-6.11
Cash Dividends Paid0.000.000.000.00
Change in Capital Stock346.10408.454.56169.32
Repurchase of Common Pref Stock0.000.000.00-0.23
Sale of Common Pref Stock346.10408.454.56169.55
Proceedsfrom Stock Options337.66405.160.00168.96
Issuance or Reduction of Debt, Net-120.83-121.90-2.330.00
Change in Long Term Debt-120.83-121.90-2.330.00
Issuance of Long Term Debt0.000.000.000.00
Reduction of Long Term Debt-120.83-121.90-2.330.00
Net Financing Active Other Cash Flow-2.16-0.510.000.00
Other Financing Activities Uses-2.16-0.510.000.00
Cash from Financing Activities223.10286.042.24169.32
Exchange Rate Effect0.390.19-0.27-0.50
Net Change in Cash-45.62-6.36-71.3986.28
Free Cash Flow-59.18-59.05-73.36-82.54
Preferred Dividends (Cash Flow)-0.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments162.55158.32176.79291.1780.21109.79
Short Term Receivables42.7635.5329.3427.8629.6928.31
Inventories0.000.000.000.000.000.00
Other Current Assets9.459.797.416.316.094.09
Total Current Assets214.76203.63213.53325.33115.99142.19
Net Property, Plant & Equipment24.8824.2426.0725.0925.9627.30
Total Investments and Advances88.99101.28108.074.474.474.47
Other Assets15.8314.8811.779.5012.9410.48
Total Assets344.46344.02359.45364.40159.36184.44
Short Term Debt Incl. Current Port. of LT Debt6.786.385.925.525.495.45
Accounts Payable4.945.753.171.961.791.97
Other Current Liabilities32.3725.8933.2830.3725.6635.98
Total Current Liabilities44.0938.0242.3737.8532.9443.41
Long Term Debt20.3419.9716.1316.27199.66197.83
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.300.320.3055.7252.9963.63
Total Liabilities64.7458.3158.80109.83285.59304.87
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.00768.57768.57
Common Equity279.73285.72300.65254.57-894.79-889.00
Total Shareholders Equity279.73285.72300.65254.57-126.23-120.43
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity279.73285.72300.65254.57-126.23-120.43
Total Liabilities & Stockholders Equity344.46344.02359.45364.40159.36184.44
Book Value Per Share3.233.323.533.05-10.73-10.95
Tangible Book Value Per Share3.233.323.533.05-10.73-10.95
Full-Time Employees--843--699
Price to Book Ratio17.306.909.56-3.14-3.22-
Return on Assets-46.99-42.32----
Return on Equity-154.23-135.31----
Return on Invested Capital-5.25-8.96-7.70-18.78-12.52-41.79
Quick Ratio4.875.365.048.603.523.28
Current Ratio4.875.365.048.603.523.28

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-15.74-27.38-24.39-50.85-9.20-32.34
Depreciation2.262.432.252.092.142.10
Other Funds (Non Cash)7.3113.2013.2539.18-5.1914.61
Funds from Operations-6.17-11.75-8.90-9.59-12.24-15.63
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.41-18.36-1.706.63-15.062.47
Cash from Operating Activities-8.58-30.10-10.60-2.96-27.30-13.17
Capital Expenditures-1.92-1.89-1.90-1.24-0.79-1.10
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments23.150.46-233.540.000.000.00
Purchase of Investments-15.78-29.54-233.540.000.000.00
Sale Or Maturity of Investments38.9230.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities21.22-1.43-235.44-1.24-0.79-1.10
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock3.236.630.46335.78-1.2373.44
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock3.236.630.46335.78-1.2373.44
Proceedsfrom Stock Options0.003.29-0.40334.77-2.0872.86
Issuance or Reduction of Debt, Net0.000.000.00-120.83-0.55-0.52
Change in Long Term Debt0.000.000.00-120.83-0.55-0.52
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.00-120.83-0.55-0.52
Net Financing Active Other Cash Flow-1.17-0.47-0.510.000.000.00
Other Financing Activities Uses-1.17-0.47-0.510.000.000.00
Cash from Financing Activities2.056.16-0.05214.94-1.7772.92
Exchange Rate Effect-0.010.26-0.070.200.29-0.24
Net Change in Cash14.69-25.11-246.16210.96-29.5858.42
Free Cash Flow-10.50-31.99-12.49-4.19-28.09-14.27

Revenue breakdown

Surgical & Medical Instruments & Apparatus2024: 125.81M 2025: 176.03M
Non-US2024: 10.77M 2025: 13.30M
United States2024: 115.04M 2025: 162.73M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.77%5.7M64.9M1.90M
2026-10-1511.30%7.3M64.9M1.81M
2026-09-3010.51%6.8M64.8M1.77M
2026-09-158.68%5.6M64.8M1.91M
2026-08-319.41%6.1M64.5M1.79M
2026-08-1410.52%6.8M64.4M1.61M
2026-07-3110.77%6.8M63.6M1.48M
2026-07-159.22%5.9M63.7M1.50M
2026-06-308.12%5.2M63.8M1.47M
2026-06-156.61%4.2M63.7M1.33M
2026-05-295.72%3.6M63.6M1.32M
2026-05-155.47%3.5M63.6M1.34M
2026-04-306.94%4.4M62.9M1.62M
2026-04-159.44%5.5M58.8M1.59M
2026-03-3111.11%6.0M54.1M1.52M
2026-03-1310.28%5.6M54.1M1.33M
2026-02-2710.15%5.5M53.7M1.21M
2026-02-138.49%4.6M53.7M1.12M
2026-01-309.24%5.0M53.6M737.59K
2026-01-156.49%3.5M53.6M632.86K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call25.0029.4032.800.004.5950.000.000.967-0.1090.007
call30.0024.5027.9023.713.79620.000.000.958-0.1060.008
call35.0019.6023.1021.003.1684.000.000.947-0.1010.010
call40.0015.2018.6014.602.73021.000.000.838-0.3040.022
call45.0011.4014.0011.302.24571.000.000.792-0.2750.026
call50.008.0011.009.862.2462231.000.694-0.3220.032
call55.005.007.106.181.84464023.000.581-0.3460.036
call60.002.955.003.831.82152611.000.467-0.3440.036
call65.001.852.952.601.6591,0070.000.337-0.2840.033
call70.000.602.001.361.68237.002.000.249-0.2500.029
call75.000.052.950.801.95543.000.000.224-0.2740.027
call80.000.002.651.012.1977.000.000.207-0.2940.026
call85.000.002.400.002.4140.000.000.194-0.3100.025
put25.000.002.150.003.0970.000.00-0.033-0.1060.007
put30.000.002.150.252.4786.000.00-0.042-0.1020.008
put35.000.000.450.331.95142.0010.00-0.053-0.0970.010
put40.000.002.550.802.63876.000.00-0.162-0.3000.022
put45.000.502.601.852.0381020.00-0.208-0.2700.026
put50.002.004.204.061.9535,4012.00-0.306-0.3170.032
put55.004.506.506.201.9174,126315-0.419-0.3400.036
put60.007.109.908.302.0311010.00-0.533-0.3380.036
put65.0010.7013.308.702.01418.000.00-0.663-0.2770.033
put70.0014.8017.800.002.2170.000.00-0.751-0.2420.029
put75.0019.1022.200.002.3250.000.00-0.776-0.2660.027
put80.0023.6026.300.002.2660.000.00-0.771-0.3230.028
put85.0027.5031.000.002.3700.000.00-0.806-0.3010.025

Latest SEC filings

0
FiledFormDescriptionPeriodLink
No filings.

Insider activity by month

MonthBoughtBuysSoldSells
2026-11002.36M2
2026-10003.24M2
2026-09007.79M11
2026-08004.46M5
2026-0700863.21K2
2026-06002.00M2
2026-0500918.27K2
2026-040061.09M5
2026-03002.42M4
2026-020058.53M4
2026-010000
2025-121.05M100
2025-110000

Institutional holders

Manager% owned
Bain Capital Life Sciences Investors, LLC9.80%
WELLINGTON MANAGEMENT GROUP LLP9.12%
FMR LLC6.32%
BlackRock, Inc.6.03%
VANGUARD PORTFOLIO MANAGEMENT LLC4.16%
BAMCO INC /NY/3.74%
VANGUARD CAPITAL MANAGEMENT LLC3.19%
Jupiter Topco LLC2.81%
Invesco Ltd.2.67%
ALLIANCEBERNSTEIN L.P.2.23%

Funds

Fund% owned
VANGUARD HEALTH CARE FUND6.72%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.86%
iShares Russell 2000 ETF2.41%
VANGUARD SMALL-CAP INDEX FUND2.07%
BARON DISCOVERY FUND1.86%
Invesco Discovery Fund1.47%
VANGUARD SMALL-CAP VALUE INDEX FUND1.31%
Select Health Care Portfolio1.09%
Fidelity Small Cap Index Fund1.02%
Select Medical Technology and Devices Portfolio0.97%

OakChart. HTFL. Cached 15 minutes.

Some panels did not load: lf, dv.